Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Semaglutide delays 4‐hour gastric emptying in women with polycystic ovary syndrome and obesity
Mojca Jensterle, Simona Ferjan, Luka Ležaič, et al.
Diabetes Obesity and Metabolism (2022) Vol. 25, Iss. 4, pp. 975-984
Open Access | Times Cited: 55

Showing 1-25 of 55 citing articles:

Anesthesia Considerations for a Patient on Semaglutide and Delayed Gastric Emptying
Erina Fujino, Kathryn W Cobb, Jay Schoenherr, et al.
Cureus (2023)
Open Access | Times Cited: 45
Quantified Metrics of Gastric Emptying Delay by Glucagon-Like Peptide-1 Agonists: A Systematic Review and Meta-Analysis With Insights for Periprocedural Management
Brent Hiramoto, Thomas R. McCarty, Nayna A. Lodhia, et al.
The American Journal of Gastroenterology (2024) Vol. 119, Iss. 6, pp. 1126-1140
Closed Access | Times Cited: 26
Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions
Ryan J. Jalleh, Christopher K. Rayner, Trygve Hausken, et al.
˜The œLancet. Gastroenterology & hepatology (2024) Vol. 9, Iss. 10, pp. 957-964
Closed Access | Times Cited: 19
Review article: Pharmacologic management of obesity ‐ updates on approved medications, indications and risks
Camille Lupiañez-Merly, Saam Dilmaghani, Kia Vosoughi, et al.
Alimentary Pharmacology & Therapeutics (2024) Vol. 59, Iss. 4, pp. 475-491
Closed Access | Times Cited: 18
Perioperative use of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for diabetes mellitus
Ketan Dhatariya, Nicholas Levy, Kim Russon, et al.
British Journal of Anaesthesia (2024) Vol. 132, Iss. 4, pp. 639-643
Open Access | Times Cited: 18
Glucagon‐like peptide‐1 receptor agonists: a narrative review of clinical pharmacology and implications for peri‐operative practice
David A. Milder, Tamara Y. Milder, S. Liang, et al.
Anaesthesia (2024) Vol. 79, Iss. 7, pp. 735-747
Open Access | Times Cited: 17
Anesthetic Considerations in Adult Patients on Glucagon-Like Peptide-1 Receptor Agonists: Gastrointestinal Focus
Girish P. Joshi
Anesthesia & Analgesia (2023)
Open Access | Times Cited: 26
Glucagon-Like Peptide-1 Agonists and General Anesthesia: Perioperative Considerations and the Utility of Gastric Ultrasound
Conner M Willson, L. Patel, Peter G. Middleton, et al.
Cureus (2024)
Open Access | Times Cited: 10
Incretin Hormone Secretion in Women with Polycystic Ovary Syndrome: Roles of Obesity, Insulin Sensitivity and Treatment with Metformin and GLP-1s
Andrea Etrusco, Mislav Mikuš, Antonio D’Amato, et al.
Biomedicines (2024) Vol. 12, Iss. 3, pp. 653-653
Open Access | Times Cited: 9
What is the evidence regarding the safety of new obesity pharmacotherapies
Josép Vidal, Lílliam Flores, Amanda Jiménez, et al.
International Journal of Obesity (2024)
Closed Access | Times Cited: 8
Tirzepatide 10 and 15 mg compared with semaglutide 2.4 mg for the treatment of obesity: An indirect treatment comparison
Carel W. le Roux, Emily R. Hankosky, Duzhe Wang, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 9, pp. 2626-2633
Open Access | Times Cited: 18
Dietary impact on fasting and stimulated GLP-1 secretion in different metabolic conditions – a narrative review
Hanna Huber, Alina Schieren, Jens J. Holst, et al.
American Journal of Clinical Nutrition (2024) Vol. 119, Iss. 3, pp. 599-627
Open Access | Times Cited: 8
Safe Continuation of Glucagon-like Peptide 1 Receptor Agonists at Endoscopy: A Case Series of 57 Adults Undergoing Endoscopic Sleeve Gastroplasty
Daniel B. Maselli, Daniel J. Lee, Danse Bi, et al.
Obesity Surgery (2024) Vol. 34, Iss. 7, pp. 2369-2374
Closed Access | Times Cited: 6
Perioperative Management of Patients Taking Glucagon-like Peptide-1 Receptor Agonists: Applying Evidence to Clinical Practice
Adriana D. Oprea, Guillermo E. Umpierrez, BobbieJean Sweitzer, et al.
Anesthesiology (2024) Vol. 141, Iss. 6, pp. 1141-1161
Closed Access | Times Cited: 6
Newer pharmacological interventions directed at gut hormones for obesity
Michael Camilleri, Andrés Acosta
British Journal of Pharmacology (2023) Vol. 181, Iss. 8, pp. 1153-1164
Closed Access | Times Cited: 14
Brown Adipose Tissue: A New Potential Target for Glucagon-like Peptide 1 Receptor Agonists in the Treatment of Obesity
Tim Hropot, Rok Herman, Andrej Janež, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 10, pp. 8592-8592
Open Access | Times Cited: 13
The maintenance of long-term weight loss after semaglutide withdrawal in obese women with PCOS treated with metformin: a 2-year observational study
Mojca Jensterle, Simona Ferjan, Andrej Janež
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 5
A real‐world disproportionality analysis of semaglutide: Post‐marketing pharmacovigilance data
Yikuan Du, Mengting Zhang, Zhenjie Wang, et al.
Journal of Diabetes Investigation (2024) Vol. 15, Iss. 10, pp. 1422-1433
Open Access | Times Cited: 5
Effect of oral semaglutide on energy intake, appetite, control of eating and gastric emptying in adults living with obesity: A randomized controlled trial
M Gabe, Astrid Breitschaft, Filip K. Knop, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 10, pp. 4480-4489
Closed Access | Times Cited: 5
Effects of GLP-1 and Other Gut Hormone Receptors on the Gastrointestinal Tract and Implications in Clinical Practice
Michael Camilleri, Camille Lupiañez-Merly
The American Journal of Gastroenterology (2023) Vol. 119, Iss. 6, pp. 1028-1037
Closed Access | Times Cited: 11
Incretin‐based therapies for the management of cardiometabolic disease in the clinic: Past, present, and future
James P. Psaltis, Jessica A. Marathe, Mau T. Nguyen, et al.
Medicinal Research Reviews (2024) Vol. 45, Iss. 1, pp. 29-65
Open Access | Times Cited: 4
Perioperative and periprocedural management of GLP-1 receptor-based agonists and SGLT2 inhibitors: narrative review and the STOP-GAP and STOP DKA-2 algorithms
Ronald Goldenberg, Jeremy Gilbert, Robyn L. Houlden, et al.
Current Medical Research and Opinion (2025), pp. 1-17
Closed Access
American Society for Gastrointestinal Endoscopy position statement on periendoscopic management of patients on glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors
Reem Z. Sharaiha, Alpana P. Shukla, Sudipta Sen, et al.
Gastrointestinal Endoscopy (2025) Vol. 101, Iss. 2, pp. 285-294
Open Access
Controversies on the effects of GLP-1 receptor agonist treatment on gastric emptying
Miguel A. Rubio, Irene Bretón Lesmes
Endocrinología Diabetes y Nutrición (English ed ) (2025), pp. 101538-101538
Closed Access
Comparing the risk of gastroparesis following different modalities for treating obesity: semaglutide versus bupropion-naltrexone versus sleeve gastrectomy – a retrospective cohort study
Chino Aneke-Nash, Kay S. Hung, Elizabeth Wall‐Wieler, et al.
BMJ Open Gastroenterology (2025) Vol. 12, Iss. 1, pp. e001704-e001704
Open Access
Page 1 - Next Page

Scroll to top